메뉴 건너뛰기
British Journal of Radiology
Volumn 89, Issue 1066, 2016, Pages
Stereotactic ablative radiotherapy and immunotherapy combinations: Turning the future into systemic therapy?
Author keywords

[No Author keywords available]
Indexed keywords

ADENOSINE TRIPHOSPHATE; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOMODULATING AGENT; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR;
EID: 84989863126     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr.20160472     Document Type: Review
Times cited : (34)
References (54)
  • 1
    • 24644441655 scopus 로고    scopus 로고
    • The role of radiotherapy in cancer treatment: Estimating optimal utilization from a review of evidence-based clinical guidelines
    • Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005; 104: 1129-37. doi: http://dx.doi.org/10.1002/cncr.21324
    • (2005) Cancer , vol.104 , pp. 1129-1137
    • Delaney, G.1    Jacob, S.2    Featherstone, C.3    Barton, M.4
  • 2
    • 58949092475 scopus 로고    scopus 로고
    • Normal tissue reactions to radiotherapy: Towards tailoring treatment dose by genotype
    • Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009; 9: 134-42. doi: http://dx. doi.org/10.1038/nrc2587
    • (2009) Nat Rev Cancer , vol.9 , pp. 134-142
    • Barnett, G.C.1    West, C.M.2    Dunning, A.M.3    Elliott, R.M.4    Coles, C.E.5    Pharoah, P.D.6
  • 3
    • 70149113060 scopus 로고    scopus 로고
    • Therapeutic effects of ablative radiation on local tumour require CD81 T cells: Changing strategies for cancer treatment
    • Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumour require CD81 T cells: changing strategies for cancer treatment. Blood 2009; 114: 589-95. doi: http://dx.doi.org/10.1182/blood-2009-02-206870
    • (2009) Blood , vol.114 , pp. 589-595
    • Lee, Y.1    Auh, S.L.2    Wang, Y.3    Burnette, B.4    Wang, Y.5    Meng, Y.6
  • 4
    • 20444406500 scopus 로고    scopus 로고
    • Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumour
    • Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumour. J Immunol 2005; 174: 7516-23. doi: http://dx. doi.org/10.4049/jimmunol.174.12.7516
    • (2005) J Immunol , vol.174 , pp. 7516-7523
    • Lugade, A.A.1    Moran, J.P.2    Gerber, S.A.3    Rose, R.C.4    Frelinger, J.G.5    Lord, E.M.6
  • 5
    • 84875552922 scopus 로고    scopus 로고
    • Immunogenic cell death in cancer therapy
    • Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51-72. doi: http://dx.doi.org/10.1146/annurev-immunol-032712-100008
    • (2013) Annu Rev Immunol , vol.31 , pp. 51-72
    • Kroemer, G.1    Galluzzi, L.2    Kepp, O.3    Zitvogel, L.4
  • 6
    • 33646704729 scopus 로고    scopus 로고
    • Radiation modulates the peptide repertoire, enhances MHC class i expression, and induces successful antitumor immunotherapy
    • Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203: 1259-71. doi: http://dx.doi.org/10.1084/jem.20052494
    • (2006) J Exp Med , vol.203 , pp. 1259-1271
    • Reits, E.A.1    Hodge, J.W.2    Herberts, C.A.3    Groothuis, T.A.4    Chakraborty, M.5    Wansley, E.K.6
  • 7
    • 84913586780 scopus 로고    scopus 로고
    • Cancer cellautonomous contribution of type i interferon signaling to the efficacy of chemotherapy
    • Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, et al. Cancer cellautonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20: 1301-9. doi: http://dx.doi.org/10.1038/nm.3708
    • (2014) Nat Med , vol.20 , pp. 1301-1309
    • Sistigu, A.1    Yamazaki, T.2    Vacchelli, E.3    Chaba, K.4    Enot, D.P.5    Adam, J.6
  • 8
    • 24144443517 scopus 로고    scopus 로고
    • The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
    • Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436: 1186-90. doi: http://dx.doi.org/10.1038/nature03884
    • (2005) Nature , vol.436 , pp. 1186-1190
    • Gasser, S.1    Orsulic, S.2    Brown, E.J.3    Raulet, D.H.4
  • 9
    • 84928205744 scopus 로고    scopus 로고
    • Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response
    • Surace L, Lysenko V, Fontana AO, Cecconi V, Janssen H, Bicvic A, et al. Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. Immunity 2015; 42: 767-77. doi: http://dx.doi.org/10.1016/j. immuni.2015.03.009
    • (2015) Immunity , vol.42 , pp. 767-777
    • Surace, L.1    Lysenko, V.2    Fontana, A.O.3    Cecconi, V.4    Janssen, H.5    Bicvic, A.6
  • 10
    • 34948820602 scopus 로고    scopus 로고
    • Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
    • Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9. doi: http://dx.doi.org/10.1038/nm1622
    • (2007) Nat Med , vol.13 , pp. 1050-1059
    • Apetoh, L.1    Ghiringhelli, F.2    Tesniere, A.3    Obeid, M.4    Ortiz, C.5    Criollo, A.6
  • 11
    • 26844468253 scopus 로고    scopus 로고
    • Cell-surface calreticulin initiates clearance of viable or apoptotic cells through transactivation of LRP on the phagocyte
    • Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through transactivation of LRP on the phagocyte. Cell 2005; 123: 321-34. doi: http://dx.doi.org/10.1016/j.cell.2005.08.032
    • (2005) Cell , vol.123 , pp. 321-334
    • Gardai, S.J.1    McPhillips, K.A.2    Frasch, S.C.3    Janssen, W.J.4    Starefeldt, A.5    Murphy-Ullrich, J.E.6
  • 12
    • 70350569295 scopus 로고    scopus 로고
    • Activation of the NLRP3 inflammasome in dendritic cells induces IL-1 beta-dependent adaptive immunity against tumors
    • Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1 beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-8. doi: http://dx.doi.org/10.1038/nm.2028
    • (2009) Nat Med , vol.15 , pp. 1170-1178
    • Ghiringhelli, F.1    Apetoh, L.2    Tesniere, A.3    Aymeric, L.4    Ma, Y.5    Ortiz, C.6
  • 13
    • 84876753532 scopus 로고    scopus 로고
    • Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells
    • Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38: 729-41. doi: http://dx.doi.org/10.1016/j.immuni.2013.03.003
    • (2013) Immunity , vol.38 , pp. 729-741
    • Ma, Y.1    Adjemian, S.2    Mattarollo, S.R.3    Yamazaki, T.4    Aymeric, L.5    Yang, H.6
  • 14
    • 84883024593 scopus 로고    scopus 로고
    • Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations
    • Honeychurch J, Melis MH, Dovedi SJ, Mu L, Illidge TM. Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations. Leuk Lymphoma 2013; 54: 2008-15. doi: http://dx.doi.org/10.3109/10428194.2013.769219
    • (2013) Leuk Lymphoma , vol.54 , pp. 2008-2015
    • Honeychurch, J.1    Melis, M.H.2    Dovedi, S.J.3    Mu, L.4    Illidge, T.M.5
  • 15
    • 84937640449 scopus 로고    scopus 로고
    • The abscopal effect of local radiotherapy: Using immunotherapy to make a rare event clinically relevant
    • Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 2015; 41: 503-10. doi: http://dx.doi.org/10.1016/j.ctrv.2015.03.011
    • (2015) Cancer Treat Rev , vol.41 , pp. 503-510
    • Reynders, K.1    Illidge, T.2    Siva, S.3    Chang, J.Y.4    De Ruysscher, D.5
  • 16
    • 84929909004 scopus 로고    scopus 로고
    • Immunoregulatory antibodies for the treatment of cancer
    • Honeychurch J, Cheadle EJ, Dovedi SJ, Illidge TM. Immunoregulatory antibodies for the treatment of cancer. Expert Opin Biol Ther 2015; 15: 787-801. doi: http://dx.doi.org/10.1517/14712598.2015.1036737
    • (2015) Expert Opin Biol Ther , vol.15 , pp. 787-801
    • Honeychurch, J.1    Cheadle, E.J.2    Dovedi, S.J.3    Illidge, T.M.4
  • 17
    • 84951832364 scopus 로고    scopus 로고
    • Stereotactic ablative radiotherapy (SABR) in patients with medically inoperable peripheral early stage lung cancer: Outcomes for the first UK SABR cohort
    • Murray L, Ramasamy S, Lilley J, Snee M, Clarke K, Musunuru HB, et al. Stereotactic ablative radiotherapy (SABR) in patients with medically inoperable peripheral early stage lung cancer: outcomes for the first UK SABR cohort. Clin Oncol (R Coll Radiol) 2016; 28: 4-12. doi: http://dx.doi.org/10.1016/j. clon.2015.09.007
    • (2016) Clin Oncol (R Coll Radiol) , vol.28 , pp. 4-12
    • Murray, L.1    Ramasamy, S.2    Lilley, J.3    Snee, M.4    Clarke, K.5    Musunuru, H.B.6
  • 18
    • 84989906297 scopus 로고    scopus 로고
    • Accessed 20 April
    • Accessed 20 April 2016. Available from: https://www.england.nhs.uk/commissioning/spec-services/npc-crg/comm-eval/
    • (2016)
  • 19
    • 84930272308 scopus 로고    scopus 로고
    • Stereotactic ablative radiotherapy versus lobectomy for operable stage i non-small-cell lung cancer: A pooled analysis of two randomised trials
    • Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015; 16: 630-7. doi: http://dx.doi.org/10.1016/S1470-2045(15)70168-3
    • (2015) Lancet Oncol , vol.16 , pp. 630-637
    • Chang, J.Y.1    Senan, S.2    Paul, M.A.3    Mehran, R.J.4    Louie, A.V.5    Balter, P.6
  • 20
    • 84989955825 scopus 로고    scopus 로고
    • Stereotactic ablative body radiation therapy (SABR): a resource. SABR UK Consortium
    • Stereotactic ablative body radiation therapy (SABR): a resource. SABR UK Consortium.
  • 21
    • 0003605672 scopus 로고    scopus 로고
    • 5th edn. Philadelphia, PA: Lippincott Williams & Wilkins
    • Hall E. Radiobiology for the radiologist. 5th edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2000.
    • (2000) Radiobiology for the Radiologist
    • Hall, E.1
  • 22
    • 84859928036 scopus 로고    scopus 로고
    • Radiation-induced vascular damage in tumors: Implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS)
    • Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 2012; 177: 311-27. doi: http://dx.doi.org/10.1667/RR2773.1
    • (2012) Radiat Res , vol.177 , pp. 311-327
    • Park, H.J.1    Griffin, R.J.2    Hui, S.3    Levitt, S.H.4    Song, C.W.5
  • 23
    • 84942915875 scopus 로고    scopus 로고
    • Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions
    • Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res 2015; 21: 3727-39. doi: http://dx.doi.org/10.1158/1078-0432.CCR-14-2824
    • (2015) Clin Cancer Res , vol.21 , pp. 3727-3739
    • Filatenkov, A.1    Baker, J.2    Mueller, A.M.3    Kenkel, J.4    Ahn, G.O.5    Dutt, S.6
  • 24
    • 84983353116 scopus 로고    scopus 로고
    • Stereotactic radiation therapy augments antigen-specific PD-1 mediated antitumor immune responses via cross-presentation of tumor antigen
    • Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, et al. Stereotactic radiation therapy augments antigen-specific PD-1 mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res 2015; 3: 345-55. doi: http://dx. doi.org/10.1158/2326-6066.CIR-14-0196
    • (2015) Cancer Immunol Res , vol.3 , pp. 345-355
    • Sharabi, A.B.1    Nirschl, C.J.2    Kochel, C.M.3    Nirschl, T.R.4    Francica, B.J.5    Velarde, E.6
  • 26
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23. doi: http://dx.doi.org/10.1056/NEJMoa1003466
    • (2010) N Engl J Med , vol.363 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3    Weber, R.W.4    Sosman, J.A.5    Haanen, J.B.6
  • 27
    • 84925222119 scopus 로고    scopus 로고
    • Nivolumab in previously untreated melanoma without BRAF mutation
    • Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-30. doi: http://dx.doi.org/10.1056/NEJMoa1412082
    • (2015) N Engl J Med , vol.372 , pp. 320-330
    • Robert, C.1    Long, G.V.2    Brady, B.3    Dutriaux, C.4    Maio, M.5    Mortier, L.6
  • 28
    • 84936791837 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
    • Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-35. doi: http://dx. doi.org/10.1056/NEJMoa1504627
    • (2015) N Engl J Med , vol.373 , pp. 123-135
    • Brahmer, J.1    Reckamp, K.L.2    Baas, P.3    Crino, L.4    Eberhardt, W.E.5    Poddubskaya, E.6
  • 30
    • 84929481481 scopus 로고    scopus 로고
    • Pembrolizumab versus ipilimumab in advanced melanoma
    • Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-32. doi: http://dx.doi.org/10.1056/NEJMoa1503093
    • (2015) N Engl J Med , vol.372 , pp. 2521-2532
    • Robert, C.1    Schachter, J.2    Long, G.V.3    Arance, A.4    Grob, J.J.5    Mortier, L.6
  • 31
    • 18544380239 scopus 로고    scopus 로고
    • Tumour-associated B7-H1 promotes t-cell apoptosis: A potential mechanism of immune evasion
    • Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Files DB, et al. Tumour-associated B7-H1 promotes t-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
    • (2002) Nat Med , vol.8 , pp. 793-800
    • Dong, H.1    Strome, S.E.2    Salomao, D.R.3    Tamura, H.4    Hirano, F.5    Files, D.B.6
  • 32
    • 42649125225 scopus 로고    scopus 로고
    • PD-1 and its ligands in tolerance and immunity
    • Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704. doi: http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331
    • (2008) Annu Rev Immunol , vol.26 , pp. 677-704
    • Keir, M.E.1    Butte, M.J.2    Freeman, G.J.3    Sharpe, A.H.4
  • 33
    • 84938329177 scopus 로고    scopus 로고
    • PD-L1 and survival in solid tumors: A meta-analysis
    • Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and survival in solid tumors: a meta-analysis. PLoS One 2015; 10: e0131403. doi: http://dx. doi.org/10.1371/journal.pone.0131403
    • (2015) PLoS One , vol.10 , pp. e0131403
    • Wu, P.1    Wu, D.2    Li, L.3    Chai, Y.4    Huang, J.5
  • 34
    • 84961182063 scopus 로고    scopus 로고
    • Human cancer immunotherapy with PD-1/PD-L1 blockade
    • Zheng P, Zhou Z. Human cancer immunotherapy with PD-1/PD-L1 blockade. Biomark Cancer 2015; 7(Suppl. 2): 15-18. doi: http://dx.doi.org/10.4137/BIC.S29325
    • (2015) Biomark Cancer , vol.7 , pp. 15-18
    • Zheng, P.1    Zhou, Z.2
  • 35
    • 84857815877 scopus 로고    scopus 로고
    • Immunologic correlates of the abscopal effect in a patient with melanoma
    • Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366: 925-31. doi: http://dx.doi.org/10.1056/NEJMoa1112824
    • (2012) N Engl J Med , vol.366 , pp. 925-931
    • Postow, M.A.1    Callahan, M.K.2    Barker, C.A.3    Yamada, Y.4    Yuan, J.5    Kitano, S.6
  • 36
    • 84880508629 scopus 로고    scopus 로고
    • Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I/II study
    • Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013; 24: 1813-21. doi: http://dx.doi.org/10.1093/annonc/mdt107
    • (2013) Ann Oncol , vol.24 , pp. 1813-1821
    • Slovin, S.F.1    Higano, C.S.2    Hamid, O.3    Tejwani, S.4    Harzstark, A.5    Alumkal, J.J.6
  • 37
    • 84904061705 scopus 로고    scopus 로고
    • Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
    • Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014; 3: e28780.
    • (2014) Oncoimmunology , vol.3 , pp. e28780
    • Grimaldi, A.M.1    Simeone, E.2    Giannarelli, D.3    Muto, P.4    Falivene, S.5    Borzillo, V.6
  • 38
    • 84872328340 scopus 로고    scopus 로고
    • Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma
    • Dovedi SJ, Melis MH, Wilkinson RW, Adlard AL, Stratford IJ, Honeychurch J, et al. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood 2013; 121: 251-9. doi: http://dx.doi.org/10.1182/blood-2012-05-432393
    • (2013) Blood , vol.121 , pp. 251-259
    • Dovedi, S.J.1    Melis, M.H.2    Wilkinson, R.W.3    Adlard, A.L.4    Stratford, I.J.5    Honeychurch, J.6
  • 39
    • 69949085196 scopus 로고    scopus 로고
    • Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody
    • Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15: 5379-88. doi: http://dx.doi.org/10.1158/1078-0432.CCR-09-0265
    • (2009) Clin Cancer Res , vol.15 , pp. 5379-5388
    • Dewan, M.Z.1    Galloway, A.E.2    Kawashima, N.3    Dewyngaert, J.K.4    Babb, J.S.5    Formenti, S.C.6
  • 40
    • 0041737455 scopus 로고    scopus 로고
    • Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma
    • Honeychurch J, Glennie MJ, Johnson PW, Illidge TM. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood 2003; 102: 1449-57. doi: http://dx.doi.org/10.1182/blood-2002-12-3717
    • (2003) Blood , vol.102 , pp. 1449-1457
    • Honeychurch, J.1    Glennie, M.J.2    Johnson, P.W.3    Illidge, T.M.4
  • 41
    • 84907486895 scopus 로고    scopus 로고
    • Acquired resistance to fractionated radiotherapy can be overcome by concurrent PDL1 blockade
    • Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PDL1 blockade. Cancer Res 2014; 74: 5458-68. doi: http://dx.doi.org/10.1158/0008-5472. CAN-14-1258
    • (2014) Cancer Res , vol.74 , pp. 5458-5468
    • Dovedi, S.J.1    Adlard, A.L.2    Lipowska-Bhalla, G.3    McKenna, C.4    Jones, S.5    Cheadle, E.J.6
  • 42
    • 84893876109 scopus 로고    scopus 로고
    • Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
    • Deng L, Liang H, Burnette B, Beckett B, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014; 124: 687-95. doi: http://dx.doi. org/10.1172/JCI67313
    • (2014) J Clin Invest , vol.124 , pp. 687-695
    • Deng, L.1    Liang, H.2    Burnette, B.3    Beckett, B.4    Darga, T.5    Weichselbaum, R.R.6
  • 43
    • 84926525215 scopus 로고    scopus 로고
    • Radiation and dual checkpoint blockade activate non-reduntant immune mechanisms in cancer
    • Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-reduntant immune mechanisms in cancer. Nature 2015; 520: 373-7.
    • (2015) Nature , vol.520 , pp. 373-377
    • Twyman-Saint Victor, C.1    Rech, A.J.2    Maity, A.3    Rengan, R.4    Pauken, K.E.5    Stelekati, E.6
  • 44
    • 84902270524 scopus 로고    scopus 로고
    • A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models
    • Adlard AL, Dovedi SJ, Telfer BA, Koga-Yamakawa E, Pollard C, Honeychurch J, et al. A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. Int J Cancer 2014; 135: 820-9. doi: http://dx.doi.org/10.1002/ijc.28711
    • (2014) Int J Cancer , vol.135 , pp. 820-829
    • Adlard, A.L.1    Dovedi, S.J.2    Telfer, B.A.3    Koga-Yamakawa, E.4    Pollard, C.5    Honeychurch, J.6
  • 45
    • 84971669532 scopus 로고    scopus 로고
    • Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to antitumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy
    • Dovedi SJ, Adlard AL, Ota Y, Murata M, Sugaru E, Koga-Yamakawa E, et al. Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to antitumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy. Oncotarget 2016; 7: 17035-46. doi: http://dx.doi. org/10.18632/oncotarget.7928
    • (2016) Oncotarget , vol.7 , pp. 17035-17046
    • Dovedi, S.J.1    Adlard, A.L.2    Ota, Y.3    Murata, M.4    Sugaru, E.5    Koga-Yamakawa, E.6
  • 46
    • 84989859912 scopus 로고    scopus 로고
    • Accessed 20 April
    • Accessed 20 April 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02562625
    • (2016)
  • 47
    • 84989879093 scopus 로고    scopus 로고
    • Accessed 20 April
    • Accessed 20 April 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02587455
    • (2016)
  • 48
    • 84989809829 scopus 로고    scopus 로고
    • Accessed 20 April
    • Accessed 20 April 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02560636
    • (2016)
  • 49
    • 84989891412 scopus 로고    scopus 로고
    • Accessed 20 April
    • Accessed 20 April 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02492568
    • (2016)
  • 50
    • 84989895182 scopus 로고    scopus 로고
    • Accessed 20 April
    • Accessed 20 April 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02239900
    • (2016)
  • 51
    • 84989945477 scopus 로고    scopus 로고
    • Accessed 20 April
    • Accessed 20 April 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02406183
    • (2016)
  • 52
    • 77955066199 scopus 로고    scopus 로고
    • Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    • Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22. doi: http://dx.doi.org/10.1056/NEJMoa1001294
    • (2010) N Engl J Med , vol.363 , pp. 411-422
    • Kantoff, P.W.1    Higano, C.S.2    Shore, N.D.3    Berger, E.R.4    Small, E.J.5    Penson, D.F.6
  • 53
    • 84989879156 scopus 로고    scopus 로고
    • Accessed 20 April
    • Accessed 20 April 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT01818986
    • (2016)
  • 54
    • 84989823404 scopus 로고    scopus 로고
    • Accessed 20 April
    • Accessed 20 April 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT01896271
    • (2016)

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.